Literature DB >> 12943977

Buruli ulcer: differences in treatment outcome between two centres in Ghana.

M A Teelken1, Y Stienstra, D E Ellen, E Quarshie, E Klutse, W T A van der Graaf, Tjip S van der Werf.   

Abstract

OBJECTIVES: Assess treatment effects by following up patients treated for Buruli ulcer in two hospitals with different treatment aspects, including widely differing surgical practices. PATIENTS/
METHODS: Treated patients were retrospectively identified from hospital records. Between 1994 and July 2000, 136 patients had been admitted for Buruli ulcer in both hospitals, and lived in areas covered in the research period. 78 (57%) Patients were included in the study. Treatment and status of the patient were analysed.
RESULTS: 27 (35%) Patients were not healed. Of the 33 patients treated in hospital A, six (18%) were not healed at follow-up, whereas of the 45 patients treated in hospital B, 21 (47%) were not healed. The length of stay in hospital A was significantly longer (P=0.002), and more operations on average were done per patient (P=0.002). In a univariate analysis, treatment in hospital A; the use of rifampicin (P=0.013); and BCG vaccination status (P=0.04) were all significantly associated with ulcer healing. Using a logistic regression model for multivariate analysis, only treatment as given in hospital A, with standard practice of wide surgical excision, appeared to predict ulcer healing independently (P=0.02).
CONCLUSIONS: This study shows large differences in treatment outcome between the two hospitals; the results support the hypothesis that extent of surgical treatment influences the chance of healing of Buruli ulcer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943977     DOI: 10.1016/s0001-706x(03)00170-0

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  14 in total

Review 1.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

Review 2.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

3.  What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us?

Authors:  Simona Rondini; Ernestina Mensah-Quainoo; Thomas Junghanss; Gerd Pluschke
Journal:  J Clin Microbiol       Date:  2006-08-23       Impact factor: 5.948

4.  Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.

Authors:  Teresa G Martins; José B Gama; Alexandra G Fraga; Margarida Saraiva; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

5.  Buruli-ulcer induced disability in ghana: a study at apromase in the ashanti region.

Authors:  Pius Agbenorku; Anthony Edusei; Margaret Agbenorku; Thomas Diby; Esenam Nyador; Geoffrey Nyamuame; Paul Saunderson
Journal:  Plast Surg Int       Date:  2012-05-15

6.  Buruli ulcer recurrence, Benin.

Authors:  Martine Debacker; Julia Aguiar; Christian Steunou; Claude Zinsou; Wayne M Meyers; Françoise Portaels
Journal:  Emerg Infect Dis       Date:  2005-04       Impact factor: 6.883

Review 7.  Pharmacologic management of Mycobacterium ulcerans infection.

Authors:  Tjip S Van Der Werf; Yves T Barogui; Paul J Converse; Richard O Phillips; Ymkje Stienstra
Journal:  Expert Rev Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.108

8.  Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control.

Authors:  Paul D R Johnson; Timothy Stinear; Pamela L C Small; Gerd Pluschke; Richard W Merritt; Francoise Portaels; Kris Huygen; John A Hayman; Kingsley Asiedu
Journal:  PLoS Med       Date:  2005-04-26       Impact factor: 11.069

Review 9.  Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Rie R Yotsu; Marty Richardson; Norihisa Ishii
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23

10.  Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.

Authors:  Richard O Phillips; Fred S Sarfo; Mohammed K Abass; Justice Abotsi; Tuah Wilson; Mark Forson; Yaw A Amoako; William Thompson; Kingsley Asiedu; Mark Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.